The JPMorgan Chase & Co. Reiterates Overweight Rating for Hikma Pharmaceuticals Plc (HIK)

The JPMorgan Chase & Co. Reiterates Overweight Rating for Hikma Pharmaceuticals Plc (HIK)

Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research note issued on Tuesday. They currently have a GBX 2,100 ($25.33) price target on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 7.36% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Jefferies Group boosted their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,000 ($24.13) to GBX 2,065 ($24.91) and gave the stock a “buy” rating in a research note on Thursday, December 15th. AlphaValue reissued a “buy” rating and issued a GBX 2,431 ($29.33) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, November 30th. Numis Securities Ltd reissued a “buy” rating and issued a GBX 2,350 ($28.35) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, November 10th. HSBC reduced their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,985 ($23.95) to GBX 1,800 ($21.72) and set a “hold” rating on the stock in a research note on Friday, November 11th. Finally, Citigroup Inc. reissued a “neutral” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, November 16th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of GBX 2,306.30 ($27.82).

Hikma Pharmaceuticals Plc (LON:HIK) opened at 1937.00 on Tuesday. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,575.00 and a 12-month high of GBX 2,703.00. The firm’s 50-day moving average price is GBX 1,810.32 and its 200-day moving average price is GBX 2,047.34. The company’s market cap is GBX 4.38 billion.

In related news, insider Said Darwazah acquired 50,000 shares of the company’s stock in a transaction dated Wednesday, November 30th. The shares were purchased at an average price of GBX 1,662 ($20.05) per share, for a total transaction of £831,000 ($1,002,533.48). Also, insider Mazen Darwazah acquired 90,730 shares of the company’s stock in a transaction dated Friday, December 16th. The shares were bought at an average price of GBX 1,849 ($22.31) per share, for a total transaction of £1,677,597.70 ($2,023,884.30).

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Related posts

Leave a Comment